Biotech Startups

Mango Materials develops biopolymers and biocomposites as sustainable alternatives to conventional plastics for consumer and industrial applications. The company focuses on creating environmentally-friendly materials sourced from natural processes.

5 investors

Manifold Bio combines AI-guided protein design with high-throughput in vivo screening to engineer tissue-targeted biologics and deliver therapeutic payloads to specific organs. The company develops a computational and experimental platform to optimize pharmacokinetics and biodistribution directly in living systems for drug discovery and development.

5 investors

Marama Labs builds CloudSpec, a UV/Vis spectroscopy instrument using patented Scatter-Free Absorption (SFA) technology to quantify nucleic acid payloads and ligands in lipid nanoparticle (LNP) samples without lysing particles or using fluorescent dyes. It serves life sciences and therapeutic development labs analyzing cloudy, scatter-prone samples such as liposomes, LNPs, metal nanoparticles, and cell or bacterial cultures.

5 investors

5 investors

Maze Therapeutics develops precision medicines for common diseases with high unmet need, using its Compass platform based on human genetics and variant functionalization. Its pipeline focuses on kidney disease, including programs for APOL1-mediated kidney disease, chronic kidney disease, and phenylketonuria.

5 investors

MBX Biosciences is a clinical-stage biopharmaceutical company developing peptide therapeutics for endocrine and metabolic diseases. It applies expertise in peptide discovery and development to create precision peptide medicines aimed at improving treatment standards for these conditions.

5 investors

Meatly produces cultivated (lab-grown) meat for use in pet food, offering an animal-free protein alternative for pets. It positions its product as a sustainable and nutritious option in the pet food industry.

5 investors

MediWound is a biotechnology company developing enzymatic treatments that selectively remove eschar tissue while preserving healthy tissue for burns and chronic wounds. Its products include NexoBrid, an approved therapy for severe thermal burns, and EscharEx, a candidate for debridement of chronic and hard-to-heal wounds, serving hospitalized and wound care patients worldwide.

5 investors

MeliBio is a California-based biotech company that develops plant-based honey alternatives using proprietary plant-science technology to replace commercial honeybees, addressing food security and supply chain challenges while supporting native pollinator biodiversity.

5 investors

MicroHarvest produces protein through natural fermentation of microorganisms, generating high-quality protein from raw materials within 24 hours. The company targets the food ingredients industry with a scalable, lower-footprint alternative to conventional animal protein.

5 investors

Automates complex biological protocols in a compact cartridge-based system for genomic sequencing

5 investors

Mission Bio develops single-cell biology tools and platforms for researchers and clinicians to enable precision medicine discovery and cancer treatment. The company serves the biomedical research and clinical diagnostics market.

5 investors

Multiply Labs builds robotic systems that automate biologics manufacturing for pharmaceutical companies. The platform orchestrates existing laboratory instruments in a closed, sterile environment to increase throughput by up to 100x while reducing costs and contamination risk.

5 investors

The Fynder Group develops a biotechnology platform using extremophile fungi to produce specialty ingredients, biopharmaceutical drugs, and bio-based materials for food, beverage, pharmaceutical, and textile applications. The company leverages proprietary filamentous fungal strains to engineer high-performance solutions across multiple industries.

5 investors

Neurogastrx is a late clinical-stage biopharmaceutical company developing therapies for patients with serious gastrointestinal (GI) disorders that have limited treatment options. It focuses on identifying and advancing drug candidates for GI conditions, with a stated focus on the United States.

5 investors

Neusignal Therapeutics develops novel drugs for central nervous system disorders, including dementia and psychiatric conditions, with research focused on calcium signaling in neurons and target discovery for brain diseases. The company serves the pharmaceutical/biotech market and is based in Tokyo, Japan.

5 investors

Neuspera Medical develops an integrated sacral neuromodulation (iSNM) system that implants a smart neurostimulator near the sacral nerve to treat urinary urge incontinence, a symptom of overactive bladder. Its device is powered by a discreet, wirelessly charged external battery worn daily, targeting patients—particularly women in the U.S.—affected by these conditions.

5 investors

Nimble Sciences develops the SIMBA GI Platform, a swallowable capsule system that autonomously collects, seals, and preserves fluid biopsies from the small intestine to generate multi-omic datasets of the GI tract. The platform is used to characterize the gut microbiome, correlate multi-omic profiles with disease states, and support therapeutic and microbiome-related research in gastrointestinal care.

5 investors

NoBACZ Healthcare develops antibiotic-free, patented liquid barrier products for wound and lesion management, creating waterproof physical barriers that block microbes as an alternative to topical antimicrobials. Its biodegradable formulas target animal health applications such as protecting hooves, horn buds and udders in farm environments, with active research collaborations with universities.

5 investors

Nocion Therapeutics develops small molecule charged sodium channel blockers (nocions) designed to silence overactive sensory nerves. The company is advancing taplucainium inhalation powder, a first-in-class therapy in Phase 2b clinical development for refractory and unexplained chronic cough, with potential applications in pain, itch, and other conditions driven by neurogenic inflammation.

5 investors

NodThera develops clinical-stage small-molecule therapies targeting inflammation for cardiometabolic and neuroinflammatory diseases, including cardiovascular disease, metabolic dysfunction, and neuroinflammation. The company operates in the biotechnology and drug development sector.

5 investors

Nomic offers an end-to-end protein profiling service built on its nELISA technology, quantifying up to 1000 informative proteins with absolute quantification for research studies. It targets researchers doing proteomics work, aiming for high-throughput, low-cost profiling in the biotech and life sciences market.

5 investors

Normunity develops biologic anti-cancer therapies that act at the interface of the immune system and tumors, targeting mechanisms tumors use to evade immune surveillance. The company builds its drug discovery pipeline through a partnership with the Lieping Chen lab at Yale School of Medicine, focusing on solid tumors.

5 investors

Nostos Genomics develops genetic testing interpretation tools to improve the accuracy, speed, and accessibility of variant analysis for patients with rare and genetic diseases. The company addresses the diagnostic bottleneck in genetic sequencing by providing better information interpretation for patients and healthcare systems.

5 investors